share_log

HC Wainwright & Co. Reiterates Buy on BioXcel Therapeutics, Maintains $10 Price Target

HC Wainwright & Co. Reiterates Buy on BioXcel Therapeutics, Maintains $10 Price Target

HC Wainwright & Co.重申买入BioXcel Therapeutics,维持10美元的目标股价
Benzinga ·  05/10 07:57

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates BioXcel Therapeutics (NASDAQ:BTAI) with a Buy and maintains $10 price target.

HC Wainwright & Co. 分析师拉古拉姆·塞尔瓦拉朱重申BioXcel Therapeutics(纳斯达克股票代码:BTAI)的买入并维持10美元的目标股价。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发